Fusion Protein Or Fusion Polypeptide (i.e., Expression Product Of Gene Fusion) Patents (Class 424/192.1)
-
Patent number: 8993519Abstract: Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.Type: GrantFiled: October 25, 2012Date of Patent: March 31, 2015Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Jason Benjamin Bock, Xia Luo
-
Patent number: 8992937Abstract: A disulfide trap, comprising an antigen peptide covalently attached to an MHC class I heavy chain molecule by a disulfide bond extending between two cysteines, is disclosed. In some configurations, a disulfide trap, such as a disulfide trap single chain trimer (dtSCT), can comprise a single contiguous polypeptide chain. Upon synthesis in a cell, a disulfide trap oxidizes properly in the ER, and can be recognized by T cells. In some configurations, a peptide moiety of a disulfide trap is not displaced by high-affinity competitor peptides, even if the peptide binds the heavy chain relatively weakly. In various configurations, a disulfide trap can be used for vaccination, to elicit CD8 T cells, and in multivalent MHC/peptide reagents for the enumeration and tracking of T cells. Also disclosed are nucleic acids comprising a sequence encoding a disulfide trap. Such nucleic acids, which can be DNA vectors, can be used as vaccines.Type: GrantFiled: August 28, 2007Date of Patent: March 31, 2015Assignee: Washington UniversityInventors: Ted H. Hansen, Daved Fremont, Janet Connolly, Lonnie Lybarger, Michael Miley, Vesselin Mitaksov, Steven Truscott
-
Patent number: 8993266Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: GrantFiled: December 20, 2012Date of Patent: March 31, 2015Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason Sagert
-
Patent number: 8992938Abstract: Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of diseases in animals caused by other Brachyspira species, including B. intermedia, B. suantatina, B. alvinipulli, B. aalborgi, B. innocens, B. murdochii, and B. pilosicoli.Type: GrantFiled: August 3, 2007Date of Patent: March 31, 2015Inventors: Matthew Bellgard, David John Hampson, Tom La
-
Patent number: 8993524Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immune suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.Type: GrantFiled: March 4, 2011Date of Patent: March 31, 2015Assignee: The Johns Hopkins UniversityInventors: Atul Bedi, Rajani Ravi
-
Publication number: 20150086584Abstract: Compositions comprising aptamers or other binding ligands provide immune cell regulatory signals and specificity to secreted cell molecules at in vivo foci of immune activity.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Applicant: University of MiamiInventors: Eli Gilboa, Randall Brennerman, Brett Schrand
-
Patent number: 8986702Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.Type: GrantFiled: May 18, 2009Date of Patent: March 24, 2015Assignee: Taiga Biotechnologies, Inc.Inventors: Yosef Refaeli, Brian Curtis Turner
-
Publication number: 20150079034Abstract: The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.Type: ApplicationFiled: June 13, 2014Publication date: March 19, 2015Inventors: Matthew SEAVEY, Yvonne Paterson, Paulo Maciag, Duane Sewell
-
Patent number: 8980274Abstract: The invention provides Ehrlichia canis antigens that can be used to detect E. canis infected animals regardless of whether the animals have been vaccinated for E. canis. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.Type: GrantFiled: January 21, 2011Date of Patent: March 17, 2015Assignee: IDEXX Laboratories, Inc.Inventors: Eugene Regis Krah, III, Melissa Beall, Thomas Patrick O'Connor, Jr., Ramaswamy Chandrashekar
-
Patent number: 8980275Abstract: The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention discloses engineered Calicivirus capsid protein sequences containing heterologous epitopes fused at internal locations such that the modified capsid proteins retain the ability to form virus-like particles when expressed in host cells. Virus-like particles comprising the chimeric proteins and vaccine formulations are also described.Type: GrantFiled: January 21, 2011Date of Patent: March 17, 2015Assignee: Takeda Vaccines, Inc.Inventors: Bryan Steadman, Ross Taylor
-
Patent number: 8980286Abstract: Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.Type: GrantFiled: February 1, 2012Date of Patent: March 17, 2015Assignee: Novartis AGInventors: Maurizio Comanducci, Mariagrazia Pizza
-
Publication number: 20150071960Abstract: Glycosphingolipids (GSLs) bearing ?-glucose (?-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with ?-glucose (?-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with ?-galactose (?-Gal) are disclosed. GSLs bearing ?-glucose (?-Glc) and derivatives of ?-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with ?-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with ?-Glc and derivatives thereof are provided.Type: ApplicationFiled: September 8, 2014Publication date: March 12, 2015Inventors: Chi-Huey WONG, Alice L. Yu, Kun-Hsien Lin, Tai-Na Chen
-
Patent number: 8974797Abstract: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.Type: GrantFiled: January 30, 2009Date of Patent: March 10, 2015Assignee: University of MassachusettsInventor: Trudy Morrison
-
Patent number: 8974794Abstract: The invention pertains to methods of using C?mX peptides (e.g., GLAGGSAQSQRAPDRVL; SEQ ID NO:2) that can bind effectively induce immune responses to membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes.Type: GrantFiled: April 16, 2014Date of Patent: March 10, 2015Assignee: Academia SinicaInventors: Tse Wen Chang, Jiun-Bo Chen, Pheidias C. Wu, Alfur F. Hung
-
Publication number: 20150064210Abstract: Compositions and methods are provided herein for predicting therapeutic outcome by measuring patient response to cellular antigen specific active immunotherapy (CASAI) using predetermined biomarkers.Type: ApplicationFiled: September 5, 2014Publication date: March 5, 2015Inventors: Debraj GuhaThakurta, James Trager, Nadeem Sheikh
-
Publication number: 20150064209Abstract: Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.Type: ApplicationFiled: September 5, 2014Publication date: March 5, 2015Inventors: Albert B. Deisseroth, Yucheng Tang, Wei-Wei Zhang, Xiang-Ming Fang
-
Publication number: 20150064211Abstract: The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of S. mansoni (SM14) or related FABPs (Fatty Acid Binding Proteins), the peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity. More particularly, the present invention relates to a method for constructing active peptide fragments, peptide fragments, immunogenic compositions and diagnostic kits using peptide fragments.Type: ApplicationFiled: November 12, 2014Publication date: March 5, 2015Applicant: FUNDAĆAO OSWALDO CRUZ - FIOCRUZInventors: Miriam Tendler, Richard Charles Garratt, Naftale Katz, Andrew John George Simpson, Frank Jefferson Alarcon de Barrientos, MĆ“nica Magno Vilar, Marilia Sirianni dos Santos Almeida
-
Patent number: 8962811Abstract: Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed.Type: GrantFiled: April 3, 2013Date of Patent: February 24, 2015Assignee: Ohio UniversityInventors: Marcia J. Kieliszewski, Jianfeng Xu, John Kopchick, Shigeru Okada, Gary Meyer
-
Patent number: 8961987Abstract: Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related E. coli enterotoxins. Such immunogenic polypeptides induce broadly reactive anti-gp120 antibodies specific for V3 epitopes that can neutralize heterologous HIV-1 subtypes and strains. These polypeptide, methods for preparing them, and methods for inducing anti-gp120 (V3-specific) antibody) responses using them are disclosed.Type: GrantFiled: August 20, 2008Date of Patent: February 24, 2015Assignees: New York University, Molsoft LLC, University of MassachusettsInventors: Susan Zolla-Pazner, Miroslaw K. Gorny, Timothy J. Cardozo, Xiang-peng Kong, Ruben Abagyan, Maxim Totrov, Shan Lu, Abraham Pinter
-
Patent number: 8961992Abstract: Epsi-gam provides a novel fusion protein with the ability to cross-link either of the Fc?RI or Fc?RII cell surface receptors with an Fc?RIIb cell surface receptor in order to block IgE-mediated biological responses.Type: GrantFiled: April 2, 2014Date of Patent: February 24, 2015Assignee: Tunitas Therapeutics, Inc.Inventors: Nolan Sigal, Gizette Sperinde
-
Patent number: 8961988Abstract: Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.Type: GrantFiled: February 19, 2014Date of Patent: February 24, 2015Assignee: GlobeImmune, Inc.Inventors: David Apelian, Thomas H. King, Zhimin Guo, Claire Coeshott
-
Patent number: 8961981Abstract: Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscular junction targeting peptide coupled to a therapeutic agent. Compositions may further include a linker peptide. Methods for targeting therapeutic agents to neuromuscular junctions and treating diseases and conditions affecting the neuromuscular junction include administering a composition including a neuromuscular junction targeting peptide coupled to a therapeutic agent.Type: GrantFiled: June 19, 2012Date of Patent: February 24, 2015Assignee: Saint Louis UniversityInventors: Henry Kaminski, Linda Kusner, Namita Satija
-
Patent number: 8961991Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: GrantFiled: March 4, 2010Date of Patent: February 24, 2015Assignee: Baylor Research InstituteInventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
-
Patent number: 8956623Abstract: The present invention relates to a recombinant fusion interferon for animals, a pharmaceutical composition thereof, and the use of the recombinant fusion interferon. The recombinant fusion interferon is represented by formula (I) or formula (II), (Porcine interferon)-(Linker)n-(Porcine immunoglobulin Fc fragment) ??(I) (Porcine immunoglobulin Fc fragment)-(Linker)n-(Porcine Interferon) ??(II) wherein n is 0 or a positive integer between 1 to 10, the recombinant fusion IFN specifically binds an antibody that specifically binds porcine interferon and an antibody that specifically binds porcine immunoglobulin Fc fragment.Type: GrantFiled: July 17, 2013Date of Patent: February 17, 2015Assignee: SBC Virbac LimitedInventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
-
Patent number: 8956611Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFFāR-Fc-fusion protein comprising the extracellular domain of BAFFāR or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXANĀ®, (rituximab),ocrelizumab, ofatumumab (HuMax-CD20Ā®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.Type: GrantFiled: October 16, 2008Date of Patent: February 17, 2015Assignees: ZymoGenetics, Inc., Ares Trading S.A.Inventors: Rafael A. Ponce, Jr., Sergio Peano, Herve Broly, Hans Otto Lennart Graffner
-
Patent number: 8956622Abstract: The present invention concern a peptidic antagonist of class III semaphorins/neuropilins complexes comprising an amino acid sequence, which is derived from the transmembrane domain of a protein selected in the group consisting of neuropilin-1, neuropilin-2, plexin-A1, plexin-A2, plexin-A3, plexin-A4, Nr-CAM, L1-CAM, integrin Beta 1 and integrin beta 2, and including at least a GxxxG motif, eventually fused to an heterologous sequence; a nucleic acid encoding for said peptidic antagonist, a pharmaceutical composition comprising such a peptidic antagonist or a nucleic acid encoding thereof and uses thereof.Type: GrantFiled: June 28, 2006Date of Patent: February 17, 2015Assignee: INSERMāInstitut National de la Sante et de la Recherche MedicaleInventors: Dominique Bagnard, Lise Roth, CĆ©cile Nasarre, Pierre Hubert, Sylvie Dirrig-Grosch, Gerard Cremel, Dominique Aunis
-
Patent number: 8956621Abstract: The present invention provides methods of treating, protecting against, and inducing an immune response against cervical dysplasia and cancer, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and an E7 and/or E6 antigen. The present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.Type: GrantFiled: December 8, 2011Date of Patent: February 17, 2015Assignees: The Trustees of the University of Pennsylvania, Advaxis, Inc.Inventors: Yvonne Paterson, John Rothman
-
Patent number: 8956618Abstract: Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.Type: GrantFiled: January 21, 2011Date of Patent: February 17, 2015Assignees: The Texas A&M University System, The Board of Trustees of the University of ArkansasInventors: Luc Berghman, Walter Bottje, Billy Hargis, Sherryll Layton
-
Publication number: 20150044251Abstract: Adding stabilizing additives to immunogenic compositions is effective in enhancing antigen stability. Suitable stabilizing additives include EDTA (ethylenediaminetetraacetic acid), sucrose, arginine, protease inhibitors, glycerol and/or citrate.Type: ApplicationFiled: December 21, 2012Publication date: February 12, 2015Inventors: Mario Contorni, Lorenzo Tarli, Anna Coslovi, Michele Sotgiu
-
Publication number: 20150044252Abstract: A massive clonal expansion of activated CD8+ T-cells with increased frequency of HPV 16-specific CD8+ T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.Type: ApplicationFiled: August 8, 2014Publication date: February 12, 2015Inventors: Marie-Lise GOUGEON, Manuelle VIGUIER, Herve BACHELEZ, Nicolas FAZILLEAU
-
Patent number: 8951530Abstract: The present invention refers to recombinant ADN molecules coding to hybrids polypeptides of different allergens from D. pteronyssinus useful for the prevention and treatment of allergies, particularly allergies caused by mites. Specifically, the invention describes hybrid proteins composed of fragments of allergens Derp p 1 y Derp p 2 with hypoallergenic characteristics and maintain their immunogenic capacity, being particularly useful for the treatment of allergy. The invention also describes the production methods of these polypeptides in heterologous expression systems. Besides, the invention describes efficient purification methods of these hybrid proteins.Type: GrantFiled: March 24, 2009Date of Patent: February 10, 2015Assignee: Bial Industrial Farmaceutica, S.A.Inventors: Juan AndrƩs Asturias Ortega, IƱaki Ibarrola Lopez De Davalillo, Maria Carmen Arilla Rodriguez, Alberto Martinez Garate
-
Patent number: 8951534Abstract: The invention relates to therapeutic vaccines for the treatment of neoplasias caused by the human papillomavirus (HPV). In particular, the vaccines of the present invention are formed by chimeric virus-like capsids of birnavirus containing papillomavirus antigens.Type: GrantFiled: November 5, 2010Date of Patent: February 10, 2015Assignee: Chimera Pharma, S.L.UInventors: Thomas Zurcher, Cayetano Von Kobbe, Juan J. Bernal, Ignacio JimĆ©nez Torres, Gloria Calderita Lucas, Margarita Rodriguez Garcia, Ana Garzon Gutierrez, Virginia Gondar Sousa E Silva, Arcadio GarcĆa De Castro, Irene Pino De La Huerga
-
Patent number: 8951532Abstract: The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria.Type: GrantFiled: January 25, 2011Date of Patent: February 10, 2015Assignee: Alere Scarborough, Inc.Inventors: Brion Mermer, William J. Palin, Nancy Turcotte
-
Patent number: 8951972Abstract: Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.Type: GrantFiled: November 14, 2011Date of Patent: February 10, 2015Assignee: Five Prime Therapeutics, Inc.Inventors: Li Long, Thomas Brennan
-
Patent number: 8945579Abstract: Methods that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. Compositions administered to the subject can further include a carrier and can be administered in single or multiple doses.Type: GrantFiled: February 6, 2013Date of Patent: February 3, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Valerian Nakaar, Albert E. Price, Lynda G. Tussey, James W. Huleatt, Thomas J. Powell, Robert K. Evans
-
Patent number: 8945589Abstract: This application relates to Group B Streptococcus (āGBSā) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.Type: GrantFiled: September 15, 2004Date of Patent: February 3, 2015Assignee: Novartis Vaccines and Diagnostics, SRLInventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
-
Patent number: 8945584Abstract: A robust and genetically stable cell culture system for Hepatitis C Virus (HCV) genotype 3a is provided. A genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7 and NS2 of strain S52 was constructed and characterized in Huh7.5 cells. S52/JFH1 and J6/JFH viruses passaged in cell culture had comparable growth kinetics and yielded similar peak HCV RNA titers and infectivity titers. Direct genome sequencing of cell culture derived S52/JFH1 viruses identified putative adaptive mutations in Core, E2, p7, NS3, and NS5A; clonal analysis revealed that all genomes analyzed exhibited different combinations of these mutations. Finally, viruses resulting from transfection with RNA transcripts of five S52/JFH1 recombinants containing these combinations of putative adaptive mutations performed as efficiently as J6/JFH viruses in Huh7.5 cells and were all genetically stable after viral passage.Type: GrantFiled: April 11, 2008Date of Patent: February 3, 2015Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Troels Kasper HĆøyer Scheel, Jesper Eugen-Olsen, Jens Bukh
-
Patent number: 8945577Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.Type: GrantFiled: April 12, 2012Date of Patent: February 3, 2015Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Normand Blais, Steve Labbe, Jan Poolman
-
Patent number: 8945575Abstract: The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers.Type: GrantFiled: December 1, 2010Date of Patent: February 3, 2015Assignees: Trustees of Boston University, Boston Medical Center CorporationInventors: Lisa Ganley-Leal, John H. Connor
-
Patent number: 8945580Abstract: The present invention provides antigens and vaccines useful in prevention of infection by Yersinia pestis. The present invention provides pharmaceutical compositions of such antigens and/or vaccines. The present invention provides methods for the production of Y. pestis protein antigens in plants, as well as methods for their use in the treatment and/or prevention of Y. pestis infection.Type: GrantFiled: February 25, 2013Date of Patent: February 3, 2015Assignee: iBio Inc.Inventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuk
-
Patent number: 8936789Abstract: Provided herein are immunogenic compositions comprising fusion proteins, the fusion proteins comprising lentivirus gp41 or a fragment thereof, a trimerization or oligomerization motif and an immunoenhancer that elicit potent and broad HIV neutralizing antibody responses in the immunized hosts. Also disclosed are methods of making and using the immunogenic compositions.Type: GrantFiled: October 16, 2009Date of Patent: January 20, 2015Assignee: New York Bood Center, Inc.Inventors: Shibo Jiang, Zhi Qi, Chungen Pan
-
Patent number: 8936792Abstract: The present invention provides improved Pseudomonas Exotoxin A (PE) molecules with high cytotoxicity and reduced immunogenicity, compositions containing the improved (PE), and methods of use.Type: GrantFiled: September 10, 2010Date of Patent: January 20, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Richard Beers, Masanori Onda
-
Patent number: 8936787Abstract: Disclosed herein are peptides and peptide analogs with multiple amphipathic ?-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway, as well as peptides that activate lipoprotein lipase, and compositions comprising such peptides or combinations thereof. Also provided herein are methods of using multi-domain amphipathic ?-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells and activate lipoprotein lipase within cells are also disclosed herein.Type: GrantFiled: April 14, 2009Date of Patent: January 20, 2015Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Alan T. Remaley, Marcelo J. A. Amar
-
Patent number: 8937157Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.Type: GrantFiled: February 6, 2014Date of Patent: January 20, 2015Assignee: University of WashingtonInventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
-
Patent number: 8932609Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.Type: GrantFiled: May 18, 2011Date of Patent: January 13, 2015Assignee: Cleveland Clinic FoundationInventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
-
Patent number: 8932598Abstract: Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin.Type: GrantFiled: June 28, 2013Date of Patent: January 13, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Ge Liu, Scott Umlauf, Uma Kavita, Hong Li, Xiangyu Liu, Bruce Weaver, Lynda Tussey
-
Patent number: 8932601Abstract: A hybrid complement-regulating protein comprises a first functional unit of a first complement regulatory protein having complement regulating properties, a first spacer sequence of at least about 200 amino acids encoding a polypeptide that does not exhibit complement regulating properties and at least a second functional unit attached to the spacer sequence. The second functional unit may be a polypeptide providing a functional unit of a second complement regulatory protein, a polypeptide derived from an immunoglobulin, or a polypeptide that enhances binding of the protein to an animal cell. The hybrid protein may also contain a second spacer sequence and a third functional unit of a complement regulatory protein, a polypeptide derived from an immunoglobulin, and a polypeptide that enhances binding of the protein to an animal cell. The optional third functional unit may be the same or different from the first or second functional units.Type: GrantFiled: November 29, 2011Date of Patent: January 13, 2015Assignee: Case Western Reserve UniversityInventors: M. Edward Medof, Lisa Kuttner-Kondo
-
Patent number: 8932605Abstract: Compositions that include Toll-like Receptor 5 agonists and at least a portion of at least one viral antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to viral infection.Type: GrantFiled: October 15, 2010Date of Patent: January 13, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Lynda G. Tussey, Alan R. Shaw, Robert S. Becker, Yi Zhang, Scott W. Umlauf, Ge Liu
-
Patent number: 8926973Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: GrantFiled: May 26, 2011Date of Patent: January 6, 2015Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
-
Patent number: 8926989Abstract: The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject.Type: GrantFiled: March 10, 2011Date of Patent: January 6, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Burbelo, Adriana Marques, Michael J. Iadarola